Literature DB >> 8958275

Attenuation of rat lung isograft reperfusion injury with a combination of anti-ICAM-1 and anti-beta2 integrin monoclonal antibodies.

S R DeMeester1, M A Molinari, T Shiraishi, K Okabayashi, J K Manchester, M R Wick, J D Cooper, G A Patterson.   

Abstract

Four different combinations of monoclonal antibodies against rat ICAM-1, CD-11a, and CD-18 were utilized to determine the relative importance of LFA-1, Mac-1, and ICAM-1 in a rat model of severe lung allograft reperfusion injury. Negative control animals were given phosphate buffered saline (the carrier solution for the antibodies), while positive control animals were rendered neutropenic by the administration of a polyclonal mouse IgG. Antibodies were given with the donor lung flush, prior to left lung graft reperfusion, or both. Isolated graft function was determined 24 hr after implantation by arterial blood gas (ABG), and after sacrifice the native and transplanted lungs underwent bronchoalveolar lavage for alveolar protein quantitation, cell count and differential, and myeloperoxidase assay. Additionally, whole lung homogenates were assayed for myeloperoxidase activity. We found that the combination of anti-ICAM-1 (1 mg/kg) added to the donor lung flush, and anti-CD11a, anti-CD18, and anti-ICAM-1 (2 mg/kg i.v. of each) given to the recipient prior to reperfusion, resulted in significantly improved lung graft pAO2 by ABG, and decreased alveolar protein, cell count, and myeloperoxidase activity compared with control animals. Improvement was less than that seen in the neutropenic recipients, however. We conclude that LFA-1, Mac-1, and ICAM-1 are all important adhesion molecules in lung allograft reperfusion injury--yet even with antibody blockade of all three there are additional mechanisms allowing for neutrophil influx into the lungs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958275     DOI: 10.1097/00007890-199611270-00016

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

Review 1.  Lung transplantation: opportunities for research and clinical advancement.

Authors:  David S Wilkes; Thomas M Egan; Herbert Y Reynolds
Journal:  Am J Respir Crit Care Med       Date:  2005-07-14       Impact factor: 21.405

Review 2.  Nanotechnology in interventional cardiology.

Authors:  Tillmann Cyrus; Samuel A Wickline; Gregory M Lanza
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011-07-11

Review 3.  Report of the ISHLT Working Group on Primary Lung Graft Dysfunction Part III: Mechanisms: A 2016 Consensus Group Statement of the International Society for Heart and Lung Transplantation.

Authors:  Andrew E Gelman; Andrew J Fisher; Howard J Huang; Maher A Baz; Ciara M Shaver; Thomas M Egan; Micheal S Mulligan
Journal:  J Heart Lung Transplant       Date:  2017-07-24       Impact factor: 10.247

Review 4.  Lung ischemia-reperfusion injury: implications of oxidative stress and platelet-arteriolar wall interactions.

Authors:  Alexander V Ovechkin; David Lominadze; Kara C Sedoris; Tonya W Robinson; Suresh C Tyagi; Andrew M Roberts
Journal:  Arch Physiol Biochem       Date:  2007-02       Impact factor: 4.076

5.  Screening and identification of key regulatory connections and immune cell infiltration characteristics for lung transplant rejection using mucosal biopsies.

Authors:  Meng-Xi Xiu; Zu-Ting Liu; Jian Tang
Journal:  Int Immunopharmacol       Date:  2020-08-10       Impact factor: 4.932

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.